Irmingard Gebert

  • Citations Per Year
Learn More
We assessed the safety, tolerability and preliminary efficacy of riociguat, a soluble guanylate cyclase stimulator, in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). In this open-label, uncontrolled pilot trial, patients received oral riociguat (1.0-2.5 mg three times daily) for 12 weeks (n=22), followed by an(More)
OBJECTIVE To investigate the efficacy and tolerability of almotriptan 12.5 mg in migraine patients who respond poorly to sumatriptan 50 mg. BACKGROUND Poor response to sumatriptan therapy for acute migraine attacks has been documented in the literature, but few controlled trials have investigated the efficacy of an alternative triptan in this subgroup of(More)
Considerable advances in the fields of molecular biology and pain research during the last decade has led to the identification of a wide range of pharmacological targets for new analgesics. Genes of interesting targets may be regulated either upwards or downwards under pathophysiological, i. e. inflammatory or neuropathic pain conditions. Targets(More)
  • 1